ANAVEX LIFE SCIENCES CORP.
About ANAVEX LIFE SCIENCES CORP.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$46.4M
- Total assets
- $103.8M
- Market cap
- $238.2M
- Operating margin
- -1098.9%
- Net margin
- -991.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $4.7M
- Operating expenses
- $51.4M
- Operating income
- -$51.4M
- Net income
- -$46.4M
- EPS (basic)
- $-0.54
- EPS (diluted)
- $-0.54
Balance sheet
- Total assets
- $103.8M
- Current assets
- $103.8M
- Total liabilities
- $8.9M
- Current liabilities
- $8.9M
- Shareholders’ equity
- $94.9M
Cash flow
- Operating cash flow
- -$39.0M
- Investing cash flow
- $29.6M
- Financing cash flow
- $9.4M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $238.2M
- EPS (diluted)
- $-0.54
- Shares outstanding
- 90.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 2, 2006
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $46.4M.
- Revenue grew 17713% from FY2021 to FY2025.
- Trading 80% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ANAVEX LIFE SCIENCES CORP..
Write a review
News about ANAVEX LIFE SCIENCES CORP.
News & sentiment via Polygon.io
